Background and objective Interstitial lung disease (ILD) remains the number one cause of
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …

Objective We sought to determine the effectiveness of mycophenolate mofetil (MMF) in
scleroderma-associated interstitial lung disease (SSc-ILD). Methods We retrospectively …

Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …

Objective. To report the efficacy and tolerability of mycophenolate mofetil (MMF) and
azathioprine (AZA) in the management of systemic sclerosis-associated interstitial lung …

Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …

Background. Interstitial lung disease (ILD) is the most common complication of systemic
sclerosis (SSc) with treatment ineffective. Objective: The aim of this meta‐analysis was to …

Objective To compare mycophenolate mofetil (MMF) with placebo for the treatment of
systemic sclerosis (SSc)–related interstitial lung disease (ILD). Methods We included …

The efficacy and safety of mycophenolate mofetil (MMF) has been studied in patients with
systemic sclerosis (SSc)-related interstitial lung disease (ILD) with moderate–severe …

Background Interstitial lung disease (ILD) frequently complicates connective tissue diseases
(CTDs). Glucocorticoids and immunomodulatory agents are regarded as mainstays of …

PURPOSE: ILD occurs in~ 40% of SSc patients and is the leading cause of death. Treating
SSc-ILD for 1 yr with oral CYC led to modest but significant improvements in lung function …